If you have been reading about GHRH analog and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-01-06. Where a claim depends on a specific study, the study is described rather than over-claimed.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
| Property | Value | Notes |
|---|---|---|
| Molecular weight | Approximately 5,136 Da | Based on the 44-amino-acid peptide backbone and N-terminal modification. |
| Appearance | White to off-white lyophilized powder | Usually supplied in single-use vials for reconstitution. |
| Solubility | Freely soluble in water; slightly soluble in some organic solvents | Peptide nature supports aqueous reconstitution. |
| Typical storage | 2–8 °C, protected from light | Refrigeration reduces degradation; avoid freezing unless specified. |
| Common analytical method | Reverse-phase high-performance liquid chromatography | Used for identity, purity, and quantification. |
| Synonyms | Tesamorelin, TH9507, GHRH(1-44) analog | Generic descriptors; avoid proprietary names. |
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone (GHRH) family. Its sequence corresponds to the fully active 44-amino-acid form of human GHRH, with a single structural modification: the addition of a trans-3-hexenoyl group at the N-terminus. That modification is not found in the naturally occurring hormone and was introduced deliberately during development to improve stability against enzymatic degradation. The compound is therefore best described as a stabilized analogue rather than a naturally occurring peptide.
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
=== Australia === In Australia, the Therapeutics Goods Administration (TGA) considers preparations to be bioequivalent if the 90% confidence intervals (90% CI) of the rate ratios, between the two preparations, of Cmax and AUC lie in the range 0.80–1.25. Tmax should also be similar between the products. There are tighter requirements for drugs with a narrow therapeutic index and/or saturable metabolism – thus no generic products exist on the Australian market for digoxin or phenytoin for instance.
Paleodemography studies demographic characteristics of past populations. Bioarchaeologists use paleodemography to create life tables, a type of cohort analysis, to understand demographic characteristics (such as risk of death or sex ratio) of a given age cohort within a population. It is often necessary to estimate the age and sex of individuals based on specific morphological characteristics of the skeleton.
== Air Force career == John Chain had a wide and varied military career, serving in a number of powerful positions. He accrued over 5,000 flying hours (including 400 combat hours) in more than 45 different military aircraft. He is a master parachutist with 66 jumps, and has been awarded the Air Force Distinguished Service Medal, the Legion of Merit, the Distinguished Flying Cross, and the Bronze Star. Chain was commissioned as a second lieutenant through the Air Force Reserve Officer Training Corps program. He received his pilot wings in 1957 and then entered combat crew training. From 1958 to 1959 the general was an F-100 Super Sabre pilot at Toul-Rosières Air Base in France, and from 1959 to 1962 at Ramstein Air Base in West Germany. General Chain then served as a flight examiner at Cannon Air Force Base, New Mexico. In 1964 he was assigned as a forward air controller in Fort Campbell, Kentucky. While there he became a master parachutist and flew Army O-1s and Air National Guard F-84 Thunderjets. In 1966 Chain flew combat missions while assigned to Tan Son Nhut Air Base in South Vietnam. He then transferred to Washington, D.C. From 1969 to 1970, Chain was an exchange officer with the U.S. Department of State. He entered the National War College in 1970 and upon graduation was assigned to Davis-Monthan Air Force Base in Arizona as deputy commander for operations. In 1972 he became deputy commander for logistics. In 1972 and 1973, Chain flew combat missions in F-4 Phantoms from Korat Royal Thai Air Force Base in Thailand.
Sources: en.wikipedia.org
== Medical uses == In the European Union empagliflozin/metformin is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycemic control:
On 9 August, Bildt compared Russia's reason for going to war with Georgia to Adolf Hitler's actions, "No state has the right to intervene militarily in the territory of another state simply because there are individuals there with a passport issued by that state or who are nationals of the state. Attempts to apply such a doctrine have plunged Europe into war in the past... And we have reason to remember how Hitler used this very doctrine little more than half a century ago to undermine and attack substantial parts of central Europe". A UN Security Council diplomat said: "Strategically, the Russians have been sending signals that they really wanted to flex their muscles, and they're upset about Kosovo." On 10 August, Russian human rights activist Sergei Kovalev called on the international community to condemn Russia's actions since Russia launched an aggression against Georgia on the pretext of defence of Russian citizens. The statement said that Russia was no longer a peacekeeper, but a party to the conflict. The statement was supported by Lev Ponomaryov and other Russian human rights activists. On 11 August, Ronald Asmus and Richard Holbrooke wrote that Georgia acted in response to provocation by Russian-backed separatists and Georgia did not want the war because it was already using soft power to attain its goals in South Ossetia.
Modern frozen section method. Frozen section histology does not give the added margin of safety by the cytotoxic Mohs paste, originally used by Mohs. This paste might have destroyed any residual cancer cells not detected by the pathologist. Missing epidermal margins. Ideally, the Mohs section should include 100% of the epidermal margin, but greater than 95% is often accepted. Vigorous scrubbing, poorly controlled initial curettage, poor tissue health, technician's error, and surgeon's error can introduce areas missing epithelial margin. Some surgeons consider 70% epithelial margin acceptable, while others suggest 100% margin. In the ideal situation, 100% of the epithelial margin should be available to be reviewed on serial sectioning of the Mohs specimen. Misreading of the pathology slide. It is difficult to differentiate between a small island of basal-cell carcinoma and a hair follicle structure. Many Mohs surgeons limit their tissue processing to include only 2 sections of tissue. This severely hampers their ability to determine if a structure is a hair follicle or a carcinoma. Two histologic sections can not fully distinguish these two nearly identical structures, and can lead to either "false negative" or "false positive" errors by either calling a section clear of tumor, or calling a section positive for tumor, respectively. Serial sectioning of the tumor is preferred by other surgeons.
Sources: en.wikipedia.org
If a person is not able to take food by mouth, glucagon by injection or insufflation may help. The treatment of hypoglycemia unrelated to diabetes includes treating the underlying problem. Among people with diabetes, prevention starts with learning the signs and symptoms of hypoglycemia. Diabetes medications, like insulin, sulfonylureas, and biguanides can also be adjusted or stopped to prevent hypoglycemia. Frequent and routine blood glucose testing is recommended. Some may find continuous glucose monitors with insulin pumps to be helpful in the management of diabetes and prevention of hypoglycemia.
==== Mental health ==== Estrogen is considered to play a significant role in women's mental health. Sudden estrogen withdrawal, fluctuating estrogen, and periods of sustained low estrogen levels correlate with a significant lowering of mood. Clinical recovery from postpartum, perimenopause, and postmenopause depression has been shown to be effective after levels of estrogen were stabilized and/or restored. Menstrual exacerbation (including menstrual psychosis) is typically triggered by low estrogen levels, and is often mistaken for premenstrual dysphoric disorder. Compulsions in male lab mice, such as those in obsessive-compulsive disorder (OCD), may be caused by low estrogen levels. When estrogen levels were raised through the increased activity of the enzyme aromatase in male lab mice, OCD rituals were dramatically decreased. Hypothalamic protein levels in the gene COMT are enhanced by increasing estrogen levels which are believed to return mice that displayed OCD rituals to normal activity. Aromatase deficiency is ultimately suspected which is involved in the synthesis of estrogen in humans and has therapeutic implications in humans having obsessive-compulsive disorder. Local application of estrogen in the rat hippocampus has been shown to inhibit the re-uptake of serotonin. Contrarily, local application of estrogen has been shown to block the ability of fluvoxamine to slow serotonin clearance, suggesting that the same pathways which are involved in SSRI efficacy may also be affected by components of local estrogen signaling pathways.
On 19 September, Trump announced that another vessel allegedly carrying drugs had been destroyed in the Caribbean and that three people had been killed; Trump stated that the vessel was "affiliated with a Designated Terrorist Organization conducting narcotrafficking in the USSOUTHCOM area of responsibility", but did not specify where within the United States Southern Command the strike occurred, the country of origin, or the alleged criminal affiliation. The Dominican Republic later announced that, under its National Directorate for Drug Control and the Dominican Navy, it had cooperated with the US Navy to locate the boat, which was about 80 nautical miles (130 km) south of Dominican-controlled Beata Island. After the boat was destroyed the Dominican Navy salvaged 377 packages of cocaine amounting to 1,000 kilograms (2,200 lb). The Directorate stated that "This is the first time in history that the United States and the Dominican Republic carry out a joint operation against narco terrorism in the Caribbean". Reuters reported that there was a previously unannounced strike on 16 October 2025, which included survivors. The US alleged that the vessel struck was a narco-submarine. Two people were killed and two survived. The survivors were rescued and detained on a US Navy ship. By 19 October, both were repatriated to their respective countries of origin, Colombia and Ecuador. On 17 October, a strike in international waters on an alleged Colombian National Liberation Army (ELN) drug vessel killed an additional three people.
== Genomics == The genome of B. cereus has been characterized and shown to contain over 5 million bp of DNA. Out of these, more than 5500 protein-encoding genes have been identified, of which the top categories of genes with known functions include: metabolic processes, processing of proteins, virulence factors, response to stress, and defense mechanisms. Many of the genes categorized as virulence factors, stress responses, and defense mechanisms encode factors in antibiotic resistance. There are approximately 600 genes which are common in 99% of the taxa of B. cereus sensu lato, which constitutes around 1% of all genes in the pan-genome. Due to the prevalence of horizontal gene transfer among bacteria, the pan-genome of B. cereus is continually expanding. The GC content of its DNA across all strains is approximately 35%. Following exposure to non-lethal acid shock at pH 5.4–5.5, the arginine deiminase gene in B. cereus, arcA, shows substantial up-regulation. This gene is part of the arcABC operon which is induced by low-pH environments in Listeria monocytogenes, and is associated with growth and survival in acidic environments. This suggests that this gene is also important for survival of B. cereus in acidic environments. The activation of virulence factors has been shown to be transcriptionally regulated via quorum-sensing in B. cereus. The activation of many virulence factors secreted is dependent on the activity of the Phospholipase C regulator (PlcR), a transcriptional regulator which is most active at the beginning of the stationary phase of growth.
Sources: en.wikipedia.org
It is a synthetic peptide analog of human growth hormone-releasing hormone. It is used clinically to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It works by stimulating pituitary growth hormone release.
Pivotal trials enrolled adults with HIV and excess visceral abdominal fat, often in the context of antiretroviral therapy. Participants were assessed mainly by computed tomography for visceral adipose tissue. The approved indication remains specific to that population.
Long-term effects on cardiovascular events, mortality, and sustained fat distribution are not well established. Most trials measured changes over months rather than years. Open questions also include whether benefits persist after treatment stops.
No. It is a peptide that acts upstream of growth hormone release, while growth hormone is the hormone itself. The two differ in size, in receptor, and in how the body clears them.